Aptose Biosciences Inc. (APTO)
NASDAQ: APTO · Real-Time Price · USD
0.398
+0.017 (4.57%)
At close: Nov 4, 2024, 4:00 PM
0.386
-0.012 (-2.94%)
After-hours: Nov 4, 2024, 7:30 PM EST

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia.

It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.

The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.

Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc.
Aptose Biosciences logo
Country Canada
Founded 1986
Industry Biotechnology
Sector Healthcare
Employees 36
CEO William Rice

Contact Details

Address:
251 Consumers Road, Suite 1105
Toronto, ON M2J 4R3
Canada
Phone 647 479 9828
Website aptose.com

Stock Details

Ticker Symbol APTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000882361
CUSIP Number 03835T200
ISIN Number CA03835T3091
SIC Code 2836

Key Executives

Name Position
Dr. William G. Rice Ph.D. Chairman, President and Chief Executive Officer
Fletcher Payne Senior Vice President, Chief Financial Officer, Chief Business Officer and Secretary
Dr. Rafael Bejar M.D., Ph.D. Senior Vice President and Chief Medical Officer
Dr. Marc Wiles Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Oct 31, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 4, 2024 8-K Current Report
Sep 6, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Aug 30, 2024 8-K Current Report
Aug 15, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Aug 2, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Jul 26, 2024 8-K Current Report